173 related articles for article (PubMed ID: 23606350)
1. Up-regulation of nuclear receptor coactivator amplified in breast cancer-1 in papillary thyroid carcinoma correlates with lymph node metastasis.
Liu MY; Guo HP; Hong CQ; Peng HW; Yang XH; Zhang H
Clin Transl Oncol; 2013 Nov; 15(11):947-52. PubMed ID: 23606350
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
3. Thyroid cancer in Egypt: histopathological criteria, correlation with survival and oestrogen receptor protein expression.
Ahmed RA; Aboelnaga EM
Pathol Oncol Res; 2015 Jul; 21(3):793-802. PubMed ID: 25576212
[TBL] [Abstract][Full Text] [Related]
4. Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma.
Dencic TM; Savin SB; Selemetjev SA; Paskas SD; Zivaljevic VR; Bozic VD; Cvejic DS
Pathol Oncol Res; 2015 Jul; 21(3):735-42. PubMed ID: 25577274
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage.
Liu MZ; Xie D; Mai SJ; Tong ZT; Shao JY; Fu YS; Xia WJ; Kung HF; Guan XY; Zeng YX
Am J Clin Pathol; 2008 May; 129(5):728-34. PubMed ID: 18426732
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of cytokeratin 17 is associated with the development of papillary thyroid carcinoma and the presence of lymph node metastasis.
Kim HS; Lee JJ; Do SI; Kim K; Do IG; Kim DH; Chae SW; Sohn JH
Int J Clin Exp Pathol; 2015; 8(5):5695-701. PubMed ID: 26191283
[TBL] [Abstract][Full Text] [Related]
7. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.
Lin P; Yao Z; Sun Y; Li W; Liu Y; Liang K; Liu Y; Qin J; Hou X; Chen L
J Proteomics; 2019 Jul; 204():103414. PubMed ID: 31195151
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
9. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma.
Xing Y; Luo DY; Long MY; Zeng SL; Li HH
World J Surg Oncol; 2014 Feb; 12():29. PubMed ID: 24485040
[TBL] [Abstract][Full Text] [Related]
10. REGγ Is Associated with Lymph Node Metastasis and T-Stage in Papillary Thyroid Carcinoma.
Qi L; He W
Med Sci Monit; 2018 Mar; 24():1373-1378. PubMed ID: 29509725
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
12. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance.
Zhou Y; Jiang HG; Lu N; Lu BH; Chen ZH
Asian Pac J Cancer Prev; 2015; 16(4):1605-8. PubMed ID: 25743839
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D receptor and progesterone receptor protein and gene expression in papillary thyroid carcinomas: associations with histological features.
Yavropoulou MP; Panagiotou G; Topouridou K; Karayannopoulou G; Koletsa T; Zarampoukas T; Goropoulos A; Chatzaki E; Yovos JG; Pazaitou-Panayiotou K
J Endocrinol Invest; 2017 Dec; 40(12):1327-1335. PubMed ID: 28589382
[TBL] [Abstract][Full Text] [Related]
14. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.
Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM
J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590
[TBL] [Abstract][Full Text] [Related]
15. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of LC3 in Papillary Thyroid Carcinomas and Lymph Node Metastases.
Li X; Lin X; Ma H
Acta Chir Belg; 2015; 115(5):356-63. PubMed ID: 26560002
[TBL] [Abstract][Full Text] [Related]
17. Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome.
Sapuppo G; Palermo F; Russo M; Tavarelli M; Masucci R; Squatrito S; Vigneri R; Pellegriti G
J Endocrinol Invest; 2017 Dec; 40(12):1355-1363. PubMed ID: 28646475
[TBL] [Abstract][Full Text] [Related]
18. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M
Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738
[TBL] [Abstract][Full Text] [Related]
19. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of p53 protein expression in papillary thyroid carcinoma.
Morita N; Ikeda Y; Takami H
World J Surg; 2008 Dec; 32(12):2617-22. PubMed ID: 18836853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
